The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GUTS | -45.02% | N/A | N/A | -89% |
| S&P | +16.9% | +95.99% | +14.39% | +37% |
Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with better solutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers. Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.27M | -56.1% |
| Gross Margin | -7333.33% | -6861.9% |
| Market Cap | $79.34M | -61.2% |
| Market Cap / Employee | $0.77M | 0.0% |
| Employees | 103 | 0.0% |
| Net Income | -$27.89M | -61.9% |
| EBITDA | -$25.81M | -13.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $22.29M | -78.3% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $56.69M | 0.6% |
| Short Term Debt | $5.03M | 3.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -95.73% | 0.0% |
| Return On Invested Capital | -103.53% | 136.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$21.30M | -12.1% |
| Operating Free Cash Flow | -$21.20M | -13.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.71 | 1.97 | 2.04 | 12.43 | 411.69% |
| Price to Sales | 1251.28 | 1079.96 | 969.17 | 4673.50 | 171.91% |
| Price to Tangible Book Value | 1.71 | 1.97 | 2.04 | 12.43 | 411.67% |
| Enterprise Value to EBITDA | -4.22 | -3.82 | -3.17 | -4.61 | -35.59% |
| Return on Equity | -196.8% | -379.8% | - | ||
| Total Debt | $62.93M | $62.50M | $61.43M | $61.72M | 0.81% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
